Mixture of betel leaf, areca nut and tobacco chewing is a risk factor for cytogenetic damage in construction workers from south India

Aim: To determine the cytogenetic effect of betel leaf, areca nut and tobacco mixture usage among female construction workers in Tamilnadu, Southern India. Methods: Totally 236 buccal cells and blood samples were collected from 80 betel quid users and 76 users with tobacco snuffing habit which were compared with 80 healthy subjects. Peripheral blood leukocyte cultures were analyzed for chromosomal aberrations (CA) and exfoliated cells from the buccal mucosa were examined for micronucleus (MN). Results: Statistically significant (p<0.01) increase in CA and MN were observed in users with snuffing habit when compared to users without snuffing habit and controls as confirmed by chi-square test. Therefore, specific biomarkers on cytogenetic endpoints might help in planning precautionary measures to reduce oral cancer risks. Conclusions: The present study can be concluded that a mixture of betel quid, areca nut and tobacco chewing/snuffing is unsafe for oral health. The genotoxic effect of smokeless tobacco should be considered in addition to other known hazards for assessing health risks

DNA damage in viscose factory workers occupationally exposed to carbon di-sulfide using buccal cell comet assay

Aim: The most important industrial use of carbon disulfide (CS2 ) has been in the fabrication of regenerated cellulose rayon by the viscose process and cellophane. CS2 leads to increased frequency of chromosomal aberrations in workers with occupational exposure to CS2 . Methods: In the present study, the DNA damage was analyzed by using buccal cell comet assay for 30 viscose plant workers who are occupationally exposed to CS2 and 30 healthy individuals. Both groups were classified as smokers and non-smokers and only the experimental subjects were classified based on the exposure period. The data were analyzed statistically by the Student’s t-test. Results: The results of this study showed increased levels of DNA damage among viscose plant workers. Conclusion: The habit of cigarette smoking among the viscose workers had a synergistic effect on inducing DNA damage

Misuse of Cardiac Lipid upon Exposure to Toxic Trace Elements—A Focused Review

Funding Information: Ricardo Lagoa acknowledges research support by the Applied Molecular Biosciences Unit-UCIBIO which is financed by national funds from FCT–Foundation for Science and Technology (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2022 by the authors.Heavy metals and metalloids like cadmium, arsenic, mercury, and lead are frequently found in the soil, water, food, and atmosphere; trace amounts can cause serious health issues to the human organism. These toxic trace elements (TTE) affect almost all the organs, mainly the heart, kidney, liver, lungs, and the nervous system, through increased free radical formation, DNA damage, lipid peroxidation, and protein sulfhydryl depletion. This work aims to advance our understanding of the mechanisms behind lipid accumulation via increased free fatty acid levels in circulation due to TTEs. The increased lipid level in the myocardium worsens the heart function. This dysregulation of the lipid metabolism leads to damage in the structure of the myocardium, inclusive fibrosis in cardiac tissue, myocyte apoptosis, and decreased contractility due to mitochondrial dysfunction. Additionally, it is discussed herein how exposure to cadmium decreases the heart rate, contractile tension, the conductivity of the atrioventricular node, and coronary flow rate. Arsenic may induce atherosclerosis by increasing platelet aggregation and reducing fibrinolysis, as exposure interferes with apolipoprotein (Apo) levels, resulting in the rise of the Apo-B/Apo-A1 ratio and an elevated risk of acute cardiovascular events. Concerning mercury and lead, these toxicants can cause hypertension, myocardial infarction, and carotid atherosclerosis, in association with the generation of free radicals and oxidative stress. This review offers a complete overview of the critical factors and biomarkers of lipid and TTE-induced cardiotoxicity useful for developing future protective interventions.publishersversionpublishe

The incidence of male breast cancer: from fiction to reality – correspondence

Male breast cancer (MBC) is uncommon, accounting for roughly 1% of all male malignancies and 1% of all breast cancers (BCs) worldwide1–4. MBC accounts for just under 0.2% of cancer-related mortality in men. Due to the low incidence of MBC, BC literature, research, clinical trials, and the advancement of novel treatments primarily focus on female BC. Male and female BC have been described to have distinct molecular and clinicopathologic characteristics5–9. According to statistical projections, ~2670 novel incidences of BC were anticipated to be detected among the male population in the United States during the year 2019, with a projected 500 fatalities resulting from this disease10. The incidence rate of BC in males is ~1 in 1000, whereas in females, it is roughly 1 in 8, resulting in a significantly higher risk for women. The overall BC rates in men and women increase progressively with age. Nevertheless, the mean age of initial diagnosis of BC in men is comparatively higher, with an average of 67 years, in contrast to women diagnosed at an average age of 62 years11. Significant gaps in understanding exist regarding the most effective approach to managing BC in male patients. Thus far, the methodologies employed in managing MBC have been primarily derived from studies on female BC patients12. Clinical trials that are currently in progress or have been planned, with an emphasis on MBC treatment, can influence the standard of care in the future. However, these trials are still in progress and will require several years. The current guideline issued by the American Society of Clinical Oncology (ASCO) provides recommendations about various crucial facets of MBC management13. In this correspondence article, we discuss the background, risk factors, and potential future treatments for treating MBC. We have tried to shed light on the importance of MBC and why it calls for a detailed discussion and research on this topic

A cooperativity between virus and bacteria during respiratory infections

Respiratory tract infections remain the leading cause of morbidity and mortality worldwide. The burden is further increased by polymicrobial infection or viral and bacterial co-infection, often exacerbating the existing condition. Way back in 1918, high morbidity due to secondary pneumonia caused by bacterial infection was known, and a similar phenomenon was observed during the recent COVID-19 pandemic in which secondary bacterial infection worsens the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) condition. It has been observed that viruses paved the way for subsequent bacterial infection; similarly, bacteria have also been found to aid in viral infection. Viruses elevate bacterial infection by impairing the host’s immune response, disrupting epithelial barrier integrity, expression of surface receptors and adhesion proteins, direct binding of virus to bacteria, altering nutritional immunity, and effecting the bacterial biofilm. Similarly, the bacteria enhance viral infection by altering the host’s immune response, up-regulation of adhesion proteins, and activation of viral proteins. During co-infection, respiratory bacterial and viral pathogens were found to adapt and co-exist in the airways of their survival and to benefit from each other, i.e., there is a cooperative existence between the two. This review comprehensively reviews the mechanisms involved in the synergistic/cooperativity relationship between viruses and bacteria and their interaction in clinically relevant respiratory infections

Corrigendum to "a review of chromium (Cr) epigenetic toxicity and health hazards" [Sci. Total environ., volume 882, 1-12, 15 July 2023, 163,483]

Refers to A review of chromium (Cr) epigenetic toxicity and health hazards Science of The Total Environment, Volume 882, 15 July 2023, Pages 163483 Mahalaxmi Iyer, Uttpal Anand, Saranya Thiruvenkataswamy, Harysh Winster Suresh Babu, Arul Narayanasamy, Vijay Kumar Prajapati, Chandan Kumar Tiwari, Abilash Valsala Gopalakrishnan, Elza Bontempi, Christian Sonne, Damià Barceló, Balachandar VellingiriThe authors regret that the printed version of the above article contained a number of errors. The correct and final version follows. The authors would like to apologize for any inconvenience caused. Incorrect Affiliation. In the published article, there was an error in affiliation [b]. Instead of ‘Zuckerberg Institute for Water Research, Jacob Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Sede Boqer Campus, Midreshet Ben-Gurion 8499000, Israel’, it should be “CytoGene Research & Development LLP, K-51, Industrial Area, Kursi Road (Lucknow), Dist.– Barabanki, 225001, Uttar Pradesh, India”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.Peer reviewe

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND: Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021. METHODS: We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined. FINDINGS: Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer. INTERPRETATION: As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

publishedVersio

Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundSmoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and what could happen if additional smoking prevalence reductions occur, is important for communicating the effect of potential smoking policies. MethodsIn this analysis, we use the Institute for Health Metrics and Evaluation's Future Health Scenarios platform to forecast the effects of three smoking prevalence scenarios on all-cause and cause-specific YLLs and life expectancy at birth until 2050. YLLs were computed for each scenario using the Global Burden of Disease Study 2021 reference life table and forecasts of cause-specific mortality under each scenario. The reference scenario forecasts what could occur if past smoking prevalence and other risk factor trends continue, the Tobacco Smoking Elimination as of 2023 (Elimination-2023) scenario quantifies the maximum potential future health benefits from assuming zero percent smoking prevalence from 2023 onwards, whereas the Tobacco Smoking Elimination by 2050 (Elimination-2050) scenario provides estimates for countries considering policies to steadily reduce smoking prevalence to 5%. Together, these scenarios underscore the magnitude of health benefits that could be reached by 2050 if countries take decisive action to eliminate smoking. The 95% uncertainty interval (UI) of estimates is based on the 2·5th and 97·5th percentile of draws that were carried through the multistage computational framework. FindingsGlobal age-standardised smoking prevalence was estimated to be 28·5% (95% UI 27·9–29·1) among males and 5·96% (5·76–6·21) among females in 2022. In the reference scenario, smoking prevalence declined by 25·9% (25·2–26·6) among males, and 30·0% (26·1–32·1) among females from 2022 to 2050. Under this scenario, we forecast a cumulative 29·3 billion (95% UI 26·8–32·4) overall YLLs among males and 22·2 billion (20·1–24·6) YLLs among females over this period. Life expectancy at birth under this scenario would increase from 73·6 years (95% UI 72·8–74·4) in 2022 to 78·3 years (75·9–80·3) in 2050. Under our Elimination-2023 scenario, we forecast 2·04 billion (95% UI 1·90–2·21) fewer cumulative YLLs by 2050 compared with the reference scenario, and life expectancy at birth would increase to 77·6 years (95% UI 75·1–79·6) among males and 81·0 years (78·5–83·1) among females. Under our Elimination-2050 scenario, we forecast 735 million (675–808) and 141 million (131–154) cumulative YLLs would be avoided among males and females, respectively. Life expectancy in 2050 would increase to 77·1 years (95% UI 74·6–79·0) among males and 80·8 years (78·3–82·9) among females. InterpretationExisting tobacco policies must be maintained if smoking prevalence is to continue to decline as forecast by the reference scenario. In addition, substantial smoking-attributable burden can be avoided by accelerating the pace of smoking elimination. Implementation of new tobacco control policies are crucial in avoiding additional smoking-attributable burden in the coming decades and to ensure that the gains won over the past three decades are not lost. FundingBloomberg Philanthropies and the Bill & Melinda Gates Foundation.Bloomberg Philanthropies and the Bill & Melinda Gates Foundation